Literature DB >> 31050772

Keeping Checkpoint Inhibitors in Check.

Daniel V T Catenacci1,2, Howard Hochster3, Samuel J Klempner4.   

Abstract

Mesh：

Year:  2019        PMID： 31050772     DOI： 10.1001/jamanetworkopen.2019.2546

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN： 2574-3805


× No keyword cloud information.
  2 in total

1.  Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy.

Authors:  Zhiren Wang; Nicholas Little; Jiawei Chen; Kevin Tyler Lambesis; Kimberly Thi Le; Weiguo Han; Aaron James Scott; Jianqin Lu
Journal:  Nat Nanotechnol       Date:  2021-08-12       Impact factor: 39.213

2.  Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.

Authors:  David Bomze; Nethanel Asher; Omar Hasan Ali; Lukas Flatz; Daniel Azoulay; Gal Markel; Tomer Meirson
Journal:  JAMA Netw Open       Date:  2020-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.